Clarifying Differences in Natural History between Models of Screening

Background. Microsimulation models are important decision support tools for screening. However, their complexity makes them difficult to understand and limits realization of their full potential. Therefore, it is important to develop documentation that clarifies their structure and assumptions. The authors demonstrate this problem and explore a solution for natural history using 3 independently developed colorectal cancer screening models. Methods. The authors first project effectiveness and cost-effectiveness of colonoscopy screening for the 3 models (CRC-SPIN, SimCRC, and MISCAN). Next, they provide a conventional presentation of each model, including information on structure and parameter values. Finally, they report the simulated reduction in clinical cancer incidence following a one-time complete removal of adenomas and preclinical cancers for each model. They call this new measure the maximum clinical incidence reduction (MCLIR). Results. Projected effectiveness varies widely across models. For example, estimated mortality reduction for colonoscopy screening every 10 years from age 50 to 80 years, with surveillance in adenoma patients, ranges from 65% to 92%. Given only conventional information, it is difficult to explain these differences, largely because differences in structure make parameter values incomparable. In contrast, the MCLIR clearly shows the impact of model differences on the key feature of natural history, the dwell time of preclinical disease. Dwell times vary from 8 to 25 years across models and help explain differences in projected screening effectiveness. Conclusions. The authors propose a new measure, the MCLIR, which summarizes the implications for predicted screening effectiveness of differences in natural history assumptions. Including the MCLIR in the standard description of a screening model would improve the transparency of these models.

[1]  Eric J Feuer,et al.  Modeling cancer natural history, epidemiology, and control: reflections on the CISNET breast group experience. , 2006, Journal of the National Cancer Institute. Monographs.

[2]  E. E. Gresch Genetic Alterations During Colorectal-Tumor Development , 1989 .

[3]  T. Wright,et al.  Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More , 2004, Obstetrics and gynecology.

[4]  A. Fendrick,et al.  Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. , 2004, Gastroenterology.

[5]  J. Romagnuolo Cost‐effectiveness of colorectal cancer screening with computed tomography colonography , 2008, Cancer.

[6]  E. Pisano,et al.  Cost-effectiveness of digital mammography breast cancer screening. , 2008, Annals of internal medicine.

[7]  Perry J Pickhardt,et al.  Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology * † , 2008, CA: a cancer journal for clinicians.

[8]  Uwe Gille,et al.  Brain growth in mallards, Pekin and Muscovy ducks (Anatidae) , 2000 .

[9]  Robert H Fletcher,et al.  Guidelines for Colonoscopy Surveillance after Polypectomy: A Consensus Update by the US Multi‐Society Task Force on Colorectal Cancer and the American Cancer Society * , † , 2006, Gastroenterology.

[10]  K. Mitsumori,et al.  Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  Amy B. Knudsen,et al.  Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. , 2010, Journal of the National Cancer Institute.

[12]  Angelo Zullo,et al.  Cost‐effectiveness of colorectal cancer screening with computed tomography colonography , 2007, Cancer.

[13]  Onchee Yu,et al.  A hierarchical non‐homogenous Poisson model for meta‐analysis of adenoma counts , 2007, Statistics in medicine.

[14]  Janneke Wilschut,et al.  At what costs will screening with CT colonography be competitive? A cost‐effectiveness approach , 2009, International journal of cancer.

[15]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[16]  R. Hayward,et al.  Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. , 2001, The American journal of medicine.

[17]  Stephen J. Swensen,et al.  Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. , 2008, Radiology.

[18]  L. Fajardo,et al.  Screening for preclinical disease: test and disease characteristics. , 2002, AJR. American journal of roentgenology.

[19]  Cancer,et al.  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial , 2010, The Lancet.

[20]  Carolyn M Rutter,et al.  An Evidence-Based Microsimulation Model for Colorectal Cancer: Validation and Application , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[21]  Iris Lansdorp-Vogelaar,et al.  A Systematic Comparison of Microsimulation Models of Colorectal Cancer , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  Amy B. Knudsen,et al.  Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.